Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Vaccine Technology 2009 Conference

Veterinary Diagnostics Markets

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

Royalty Financing Agreements in Pharma, Biotech and Diagnostics

New Products

Attention Deficit Hyperactivity Disorder: Diagnosis and Treatment

Bioinformatics Market Potential

Biotechnology in the European Union; Trends, Investing & Country Profiles

China Pharmaceutical Industry: Analysis and Market Trends

European Generic Drug Market Potential

Global Biotechnology Markets Trends

Strategic Alliances in World Pharma and Biotech Markets

Understanding China's Chemical Industry

Understanding Genomics and Global Health Impacts

Understanding Pharmacogenomics

BioPortfolio | Donald Macarthur | Pharmacy Liberalisation in Europe: Prospects and Implications

Pharmacy Liberalisation in Europe: Prospects and Implications

Very little in the pricing environment in Europe is predictable to pharmaceutical companies and only rarely is much notice given of change. But before the end of 2009, if the European Court of Justice accepts the arguments put to it forcefully by the European Commission and by DocMorris, then revolutionary reform among industry's main customer group, the community pharmacist, in several of the main countries, including 4 of the EU-5, will get the green light. The main issue to be resolved, whether national regulations on pharmacy ownership and establishment of new premises infringe EU law, is of wider importance than for the pharmacy profession alone. It amounts to a battle over control of healthcare provision between Brussels and the member states, with the outcome also of great significance to patients, wholesalers, manufacturers and payers.

'Pharmacy Liberalisation in Europe: Prospects and Implications' provides fully researched, up-to-date information and interpretation on what deregulation could mean to all participants in the medicines' market. Whether your interest is in marketing prescription brands, generics or OTCs, in their distribution, or in paying the bill for them, this report is for you. To be forewarned of what might happen will allow adequate preparation for it.

The report addresses:

o Background and current status of infringement actions brought by the European Commission against seven EU member states, plus the key ECJ case involving the controversial DocMorris pharmacy in the Germany city of Saarbrücken.

o The arguments for and against reform.

o What might happen, who would be the winners and the losers.

o Details of the current ownership structure and ownership rules for pharmacies in countries all across Europe from Iceland to Cyprus.

o Interdependency of pharmacy and wholesaling, and how this could evolve.

o What lessons can be found from markets that have already deregulated.

o How vertical integration impacts the reimbursement of multisource products and the response by payers to this.

o The latest on plans to break up Apoteket's pharmacy monopoly in Sweden.

o Liberalisation of OTC sales channels.

Author: Donald Macarthur

First published: September 2008

Length: 76 pages

Format:PDF
Table of Contents
Price: $784.00 / €524.03

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions